Poster presentations (as of 9/14/23)

Poster Session A
Thursday, October 12 | 12:30 pm-4:00 pm
Level 2, Exhibit Hall D

A001: *Mapping the interaction between C-type lectin domain group 14A and Multimerin 2.* Aleen Baber, University of Birmingham, Birmingham, United Kingdom.

A002: *The utility of pre-clinical trials in glioblastoma patient-derived xenografts (PDXs) models for informing clinical trial development of therapeutic strategies*. Danielle M. Burgenske, Mayo Clinic, Rochester, MN United States.

A003: *A novel treatment strategy for high-risk and relapse/refractory hepatoblastoma*. Andres F. Espinoza, Baylor College of Medicine, Houston, TX United States.

A004: *Enhanced antitumor immunity by ASP1570 in mouse models: A novel DGKζ inhibitor offers a potential immunotherapy for treating cancer*. Osamu Ikeda, Immuno-Oncology, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.

A005: *Preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers in humanized mouse models*. Glenn Smits, EPO GmbH, Berlin, Germany.

A006: *Characterizing antitumor response of PARP Inhibitor and synergy of docetaxel and PARP Inhibitor in BRCA1/2 Mutant TNBC breast cancer PDX Models*. Jingjing Wang, Crown Bioscience Inc., San Diego, CA United States.

A007: *Preclinical Bone Metastasis Technology Platform – Predictive evaluation of Experimental Therapies on Bone Metastasis*. Tiina E. Kähkönen, OncoBone, Kiviniemi, Finland.

A008: *An in vivo screening platform based on Ba/F3 kinase-engineered cell lines for discovering next-generation kinase inhibitors*. Stephanie Wang, Kyinno Biotechnology, Waltham, MA United States.

A009: *A New Version of NGS-QC-PANEL Enables Better Authentication and Characterization of Human and Mouse Samples*. Wubin Qian, Crown Bioscience Inc., Suzhou, China (Mainland).

A010: *Gloriosine induces cell cycle arrest by autophagic cell death through negative regulation of YAP transcriptional activity in non-small cell lung cancer. Gloriosine is a potent alkaloid derivative having potent anti cancer activity*. Biswajit Dey, National Institute of Pharmaceutical Education and Research Hyderabad, Hyderabad, India.

A011: *NRBF2 induces radioresistance by increasing autophagy mediated metabolite replenishment in glioblastoma*. Eunguk Shin, Pusan National University, Busan, Korea, Republic of.

A012: *Role of STX1A in mediating Cathepsin G's entry into human colorectal cancer cells*. Valery Rozen, Michigan State University College of Human Medicine, Grand Rapids, MI United States.

A013: *Leukemic stem cell differentiation visible at single-cell resolution in AML patients treated with BRG1/BRM inhibitor FHD-286*. GiNell Elliott, Foghorn Therapeutics, Cambridge, MA United States.

A014: *Deep Learning-Driven Drug Discovery: A Breakthrough Algorithm and its Implication in Lung Cancer Therapy Development*. Dmitrii K. Chebanov, BioALg Corp., Covina, CA United States.

A015: *Prediction of immunotherapy response using mutations to cancer protein assemblies*. JungHo Kong, UCSD, San Diego, CA United States.

A016: *Novel LEF1 gene structural variants in T-cell acute lymphoblastic leukemia Patient-Derived Xenografts models*. Yueying Wang, Crown Bioscience, Suzhou, China (Mainland).

A017: *Computer simulation and quantification of the mass-action law-base pharmacodynamics parameters for anti-cancer and anti-viral therapeutics for single drugs and their combinations*. Ting-Chao David Chou, PD Science, LLC, Paramus, NJ United States.

A018: *Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterations*. Eldad D. Shulman, National Cancer Institute, Bethesda, MD United States.

A019: *eIF4A and PDCD4 expression in TNBC underlies sensitivity to natural product translation inhibitor*. Alagu Subramanian, Baylor University, Waco, TX United States.

A020: *Reversing triple negative breast cancer stem cells by disrupting the Notch signaling pathway via BCL6 targeting*. Massimo Di Nicola, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

A021: *Screening of Novel therapeutic markers for Ovarian Cancer Stem Cells*. Sang Hyun Min, K-MEDI hub, Daegu, Korea, Republic of.

A022: *CDK2 inhibition demonstrates synthetic lethality in SCLC through apoptotic induction*. Nathan Schomer, Allorion Therapeutics, Natick, MA United States.

A023: *Preclinical development of PKMYT1 and WEE1 inhibitor combinations*. David Gallo, Repare Therapeutics, St-Laurent, QC Canada.

A024: *Preclinical profile of novel and potent small molecule inhibitors of KIF18A inhibitors in chromosomally unstable solid tumor lines*. Sukanya Patra, Satya Pharma Innovations, Hyderabad, India.

A025: *Cytostatic effects and expression modulations in cell cycle genes by a 3rd generation alkyl-phospholipid (erufosine) in liver and lung cancer cells*. Asim Pervaiz, Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan.

A026: *Synthesis and structure-activity studies of DNA- and RNA-binding nucleopeptides with a cell penetrating potential*. Stefano Tomassi, University of Naples Federico II, Naples, Italy.

A027: *A photoactivatable microtubule-targeting rigidin prodrug*. Alexander Kornienko, Texas State University, San Marcos, TX United States.

A028: *Cornulin, An epithelial differentiation marker: A novel antitumor protein and prognosticator in patients with Head and Neck Squamous Cell Carcinoma*. Rajandeep Kaur, Post graduate institute of medical education and research, Chandigarh, India.

A029: *Identification of cancer-specific CPP from human telomerase peptide library and its drug delivery potential in anti-cancer strategy*. Won Jun Shon, Seoul National University School of Dentistry, Seoul, Korea, Republic of.

A030: *Treatment with sustained-release anagrelide reduces tumor volume and has antiproliferative effects in a patient-derived GIST xenograft mouse model*. Harri Sihto, University of Helsinki, Helsinki, Finland.

A031: *Development of poly lactic acid based biodegradable nanoparticles for co-delivery of pirarubicin and gemcitabine for synergistic anti-tumor efficacy*. Priya Gupta, IIT Delhi, New Delhi, India.

A032: *Cell membrane coated- Biomimetic biodegradable nanoparticles for tumor targeted delivery of THP-doxorubicin using polylactic acid based redox responsive polymer*. Harshdeep Kaur, IIT-Delhi, New Delhi, India.

A033: *Anti-proliferative effects of lentinan, a beta-glucan from shiitake mushroom (lentinula edodes)*. Titus Sombuor, Texas Woman's University, Denton, TX United States.

A034: *Synthesis and biological activities of a novel series of "combi-molecules" designed to delay metabolic dealkylation prior to crossing the blood brain barrier in the context of optimizing their potency against glioblastoma multiforme*. Ana Belen Fraga-Timiraos, The Research Institute of the McGill University Health Center, Montreal, QC Canada.

A036: *A subset of lung adenocarcinomas defined by high-level ERBB2 amplification is vulnerable to HER2-targeted therapy*. Igor Odintsov, Brigham and Women's hospital, Boston, MA United States.

A037: *Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer*. Gizem Karsli Uzunbas, The Broad Institute of MIT and Harvard, Cambridge, MA United States.

A038: *Selective therapeutic antibodies against oncogenic mutations of HER2 ectodomain*. Injin Bang, New York University Langone Health, New York, NY United States.

A039: *Carnitine palmitoyltransferase IA: An emerging potential metabolic target to counteract HER2-targeted therapy resistance in HER2-positive breast cancer*. Serenella M. Pupa, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

A040: *Characterization of a humanized monoclonal antibody targeting cancer-expressed EGFR*. Tamara G. Fernandes Costa, CCR, NCI, NIH, Bethesda, MD United States.

A041: *FHD-286, a potent and selective inhibitor of BRG1 and BRM, shifts metastatic uveal melanoma tumor towards a less immunosuppressive state in patient samples*. Liv H. Johannessen, Foghorn Therapeutics, Cambridge, MA United States.

A042: *Targeting vulnerabilities arising from global DNA hypomethylation in cancer*. Pallabi Mustafi, Fred Hutchinson Cancer Center, Seattle, WA United States.

A043: *CDK8/19-regulated transcriptional reprogramming: A druggable driver of castration-resistant prostate cancer*. Mengqian Chen, Senex Biotechnology, Inc., Columbia, SC United States.

A044: *The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER+ breast cancer*. Gopinath S. Palanisamy, Olema Oncology, San Francisco, CA United States.

A045: *EZH2 inhibition re-sensitizes drug resistant triple-negative breast cancer PDX models to Eribulin*. Kathryn Bozek, McGill University, Montreal, QC Canada.

A046: *Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers*. Susanta Samajdar, Aurigene Oncology Ltd, Bengaluru, India.

A047: *Discovery of potent and paralog selective PROTAC degraders of CBP or p300 proteins for the treatment of various cancers*. Susanta Samajdar, Aurigene Oncology Limited, Bangalore, India.

A048: *Novel murine models of ARID1A and PBRM1-deficient cholangiocarcinoma for preclinical discovery and development*. Caitlin B. Conboy, Division of Medical Oncology, Mayo Clinic, Rochester, MN United States.

A049: *Investigation of FHD-609, a potent degrader of BRD9, in preclinical models of acute myeloid leukemia (AML)*. Claudia Dominici, Foghorn Therapeutics, Cambridge, MA United States.

A050: *A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors*. Apostolia Tsimberidou, University of Texas M.D. Anderson Cancer Center, Houston, TX United States.

A052: *Discovery and characterization of a p300-selective degrader demonstrates potent anti-tumor activity in preclinical models of prostate cancer*. Mike Russell, Proteovant Therapeutics, King of Prussia, PA United States.

A053: *The dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 induces functional differentiation and splicing defects in preclinical models of acute myeloid leukemia (AML)*. Ashley K. Gartin, Foghorn Therapeutics, Inc., Cambridge, MA United States.

A054: *Interleukin-16 is a novel target to prevent age-associated epigenetic changes leading to malignant transformation associated with ovarian high-grade serous carcinoma (HGSOC)*. Jessica Ramirez, Rush University Medical Center, Chicago, IL United States.

A055: *Discovery of a novel, highly potent VHL-recruiting EZH2 PROTAC degrader targeting MLL-r AML*. Julia Velez, Icahn School of Medicine at Mount Sinai, New York, NY United States.

A056: *Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer*. Gabriel J. Sandoval, Foghorn Therapeutics, Cambridge, MA United States.

A057: *Small molecule microarray screening identifies novel androgen receptor ligands*. Marek J. Kobylarz, Kronos Bio, Cambridge, MA United States.

A058: *Investigating the molecular role of BRD9 in synovial sarcoma*. Salih Topal, Foghorn Therapeutics, Cambridge, MA United States.

A059: *Small molecule microarray lysate screen identifies bromodomain ligands that target the MYC transcription regulatory network*. Emily B. Cohen, Kronos Bio, Cambridge, MA United States.

A060: *Discovery of potent and selective EP300 degraders with anti-cancer activity*. Mark Zimmerman, Foghorn Therapeutics, Cambridge, MA United States.

A061: *The LSD1 inhibitor iadademstat shows preclinical efficacy in malignant peripheral nerve sheath tumor cells and synergistic effects in combination*. Ana Limón, Oryzon Genomics, Barcelona, Spain.

A062: *Discovery and characterization of potent and selective protein arginine methyltransferase 5 (PRMT5) inhibitors*. Seungah Jun, Hanmi Pharmaceutical Co. Ltd., Hwaseong, Korea, Republic of.

A063: *Epigenetic regulation of Neuregulin 1 promotes breast cancer progression associated to hyperglycemia*. Jiyoung Park, Ulsan National Institute of Science and Technology, Ulsan, Korea, Republic of.

A064: *Establishing the cellular and molecular impacts of the dual BRM/BRG1 inhibitor FHD-286 on pre-clinical models of non-small cell lung cancer (NSCLC)*. Molly M. Wilson, Foghorn Therapeutics, Cambridge, MA United States.

A065: *Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and osimertinib*. Alexander I. Spira, Virginia Cancer Specialists, Fairfax, VA United States.

A066: *TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice*. Ismail Meraz, University of Texas MD Anderson Cancer Center, Houston, TX United States.

A068: *Site-specific modification of nanobodies for ImmunoPET of Liver Cancer utilizing Self-labeling nanobody-tag pair (SLANT) technology*. Stanley Fayn, NCI/NIH, Bethesda, MD United States.

A069: *Generation of Llama-Derived Phage Display Library Specific to Hepatocellular Carcinoma Tumor Targets*. Divya Nambiar, NIH/NCI, Bethesda, MD United States.

A070: *Olaparib enhances radiation-induced Type I interferon and sensitizes pancreatic cancer to PD-L1 immune checkpoint inhibition*. Victoria M. Valvo, University of Michigan, Ann Arbor, MI United States.

A071: *Pancreas organoid immune co-culture system identifies immunomodulators in pancreas adenocarcinoma*. Johnathan D. Ebben, Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI United States.

A072: *Ghrelin deletion reduces mammary tumor growth and enhances response to immunotherapy*. William H. Walker II, West Virginia University, Morgantown, WV United States.

A074: *Discovery of WTX-330, a clinical stage conditionally activated IL-12 INDUKINE™ therapeutic with potent antitumor activity in murine syngeneic tumor models resistant to checkpoint blockade*. Andres Salmeron, Werewolf Therapeutics, Inc., Watertown, MA United States.

A076: *Discovery and characterization of a novel, immunoproteasome activator that modulates the immunopeptidome, increases MHC class I antigenic presentation and enhances antitumor immunity*. Priyanka S. Rana, Case Western Reserve University School of Medicine, Clevleand, OH United States.

A077: *A novel, tumor-targeted immunocytokine comprising an anti-PD-L1 Affimer® fused to IL-15 exhibits potent anti-tumor activity*. Victoria Juskaite, Avacta Life Sciences, London, United Kingdom.

A078: *Intratumoral administration of ultra high-concentration Nitric Oxide (UNO) and anti-PD-1 treatment leads to high tumor regression rates and prolonged survival in tumor-bearing mice*. Yana Epshtein, Beyond Cancer, Rehovot, Israel.

A079: *FHD286 is a BRG1/BRM ATPase inhibitor showing efficacy in NSCLC models and is applicable to NSCLC patients both as a single agent treatment and in combination with current standards of care*. Oliver Mikse, Foghorn Therapeutics, Cambridge, MA United States.

A080: *Establishment and characterization of a panel of prostate cancer XPDX models with differential AR-V7 staining and enzalutamide response*. Jim Lund, XenoSTART, San Antonio, TX United States.

A081: *Patient-derived xenograft models from hematological malignancies for preclinical drug development and biomarker research*. Christian Rupp, Experimental Pharmacology & Oncology Berlin-Buch GmbH, Berlin, Germany.

A083: *A breast cancer PDX-derived cell lines preclinical platform as a tool for pharmacological screening and functional studies*. Olivier Déas, XenTech, Evry, France.

A084: *Use of the natural nucleotide, GTP, is essential for the identification of potent, active-state KRAS^{G12C} inhibitors that bind in the switch II pocket*. Bin Wang, BridgeBio Oncology Therapeutics, South San Francisco, CA United States.

A085: *BI KRAS^{multi}, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in preclinical models and validates wild-type amplified KRAS as a therapeutic target*. Antonio Tedeschi, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

A086: *NST-628 is a novel molecular glue that inhibits signaling and pathway reactivation in oncogenic RAS-MAPK cancers*. Bradley Quade, Nested Therapeutics, Inc., Cambridge, MA United States.

A087: *BI KRAS^{multi}, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V-driven preclinical models*. David H. Peng, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

A088: *NST-628 is a potent, best-in-class MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers*. Meagan B. Ryan, Nested Therapeutics, Cambridge, MA United States.

A089: *NST-628 is a potent, fully brain-penetrant, RAS/MAPK pathway molecular glue inhibitor with efficacy in CNS tumor models*. Meagan B. Ryan, Nested Therapeutics, Cambridge, MA United States.

A090: *Preclinical efficacy of BDTX-4933, a brain-penetrant, orthosteric RAF inhibitor, targeting oncogenic RAF conformation shared by groups of BRAF and upstream driver mutations*. Yoon-Chi Han, Black Diamond Therapeutics, New York, NY United States.

A091: *The class I selective, oral HDAC inhibitor bocodepsin enhances the response to MAPK pathway inhibitors in multiple tumor types with mutations in MAPK pathway signaling proteins*. Rich Woessner, OnKure Therapeutics, Boulder, CO United States.

A092: *Determinants of sensitivity to BI KRAS^{multi} inhibitor using high-throughput in-vitro drug screens*. Fiorella Schischlik, Boehringer Ingelheim, Vienna, Austria.

A093: *Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo*. Anna Travesa, Immuneering, San Diego, CA United States.

A094: *Preclinical characterization of HMPL-415, a second-generation SHP2 inhibitor*. Jia Hu, HUTCHMED Limited, Shanghai, China (Mainland).

A095: *The paradox-breaker BRAF inhibitor plixorafenib (FORE8394) efficiently inhibits non-V600 mutations and fusions*. Limor Cohen, FORE Biotherapeutics, Ness Ziona, Israel.

A096: *RAS mutation status predicts activity of the SHP2 inhibitor TNO155 in RAS-pathway driven fusion-negative rhabdomyosarcoma*. Andrew Baker, Johns Hopkins School of Medicine, Baltimore, MD United States.

A097: *HBI-2438, HUYABIO selective KRAS^{G12C} inhibitor with BBB penetration, inhibited tumor growth in a metastatic brain model as single agent and also displayed synergy in combination with HBI-2376 (HUYABIO SHP2 inhibitor) in a CRC PDX model*. Farbod Shojaei, HUYABIO International, San Diego, CA United States.

A098: *HBI-2376, HUYABIO clinical stage SHP2 inhibitor, displays efficacy signal in patients with KRAS mutations in early clinical studies*. Farbod Shojaei, HUYABIO International, San Diego, CA United States.

A099: *Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS driven tumors*. Srikant Viswanadha, Satya Pharma Innovations, Hyderabad, India.

A100: *Large-scale cell line profiling of small molecule MAPK pathway inhibitors identifies important differences between therapeutics acting on the same biochemical target*. Jeffrey J. Kooijman, Oncolines B.V., Oss, Netherlands.

A101: *Novel KRAS inhibitors suppress MAPK pathway signalling and display potent anti-proliferative activity across a broad range of KRAS mutant cell lines*. Inder Bhamra, Redx Pharma, Macclesfield, United Kingdom.

A103: *Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile*. Kate Brown, National Institutes of Health, National Cancer Institute, Bethesda, MD United States.

A104: *ADAR1-associated metabolic vulnerabilities in triple-negative breast cancer*. Che-Pei Kung, Washington University in St. Louis, St. Louis, MO United States.

A105: *Pharmacological inhibition of nicotinamide adenine dinucleotide (NAD^+) production enzyme nicotinamide phosphoribosyltransferase (NAMPT) impairs cellular survival, energy metabolism, and tumor growth in neuroblastoma (NB) models*. Sophia Varriano, NCI-NIH, Bethesda, MD United States.

A106: *Pharmacological activation of CLIP3 reduces radioresistance by suppressing stemness and glycolysis in glioblastoma*. Hyunkoo Kang, Pusan National University, Busan, Korea, Republic of.

A107: *Diacylglycerol kinase B mediates radioresistance by regulating mitochondrial lipotoxicity in glioblastoma*. Haksoo Lee, Pusan National University, Busan, Korea, Republic of.

A108: *Metabolic oriented treatment: Efficacy of sr59230a 3-adrenergic receptor antagonist, and sr plus buformin® in Ewing sarcoma*. Cristina Banella, Meyer Children's Hospital IRCCS, Florence, Italy.

A109: *Targeting pyrimidine biosynthesis as a metabolic vulnerability in brain metastasis*. Shawn C. Chafe, McMaster University, Hamilton, ON Canada.

A110: *Identifying sensitive patient populations for CDK7 inhibitors using cell panel screens and bioinformatic approaches*. Keisha Hearn, Astex Pharmaceuticals, Cambridge, United Kingdom.

A111: *Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma*. Abdelrahman Yousef, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

A112: *A Semi-Supervised Approach to Classify Atypical BRAF Mutations to Identify Effective Targeted Therapies in Colorectal Cancer*. Abhinav B. Madduri, University of Texas MD Anderson Cancer Center, Houston, TX United States.

A113: *National Multidisciplinary Tumor Board improves diagnostic stratification and therapeutic management in Cancers of Unknown Primary*. Ivan Bieche, Institut Curie, Paris, France.

A114: *Naturally occurring LAG3-blocking recombinant antibodies as a novel class of checkpoint inhibitors*. Ilya Tsimafeyeu, ILGEN Inc., New York, NY United States.

A115: *mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): Final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)*. Helen L. Robbins, University of Birmingham, Birmingham, United Kingdom.

A116: *TSC1 mutant bladder cancer is characterized by a TSC-associated gene expression signature due to TFE3 transcriptional activity*. Magdalena Losko, Brigham and Women's Hospital, Harvard Medical School, Boston, MA United States.

A117: *Evaluation of nab-sirolimus in combination with PI3K pathway inhibitors to overcome PI3K/mTOR resistance in PI3K-mutant breast cancer cell lines*. Andrew Kwon, Aadi Bioscience, Pacific Palisades, CA United States.

A118: *Somatic mutations in the PIK3CA gene and its prognostic implications among Ethiopian Breast cancer patients*. Zelalem Desalegn Woldesonbet, Addis Ababa University, Addis Ababa, Ethiopia.

A119: *Diet boosts the anti-cancer role of aspirin in PIK3CA-induced tumorigenesis*. George Poulogiannis, The Institute of Cancer Research, London, United Kingdom.

A120: *Differentilal roles of PI3K catalytic kinases in glioblastoma's chemoresistance*. Zhi Sheng, Fralin Biomedical Research Institute, Roanoke, VA United States.

A121: *Temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer*. Jibran Ahmed, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

A122: *Deciphering macrophage targeting cancer immunotherapies using a novel in vitro assay modelling the tumor microenvironment*. Justyna Rzepecka, Concept Life Sciences, Edinburgh, United Kingdom.

A123: *Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials*. Ezra Rosen, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY United States.

A124: *Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment*. James Miles, HAWK Biosystems, Derio, Spain.

A125: *Clinical evaluation of a functional combinatorial precision medicine platform to predict combination immunotherapy responses in hematological malignancies*. Edward K. Chow, National University of Singapore, Singapore, Singapore.

A126: *Characterization of proteasome stress response reporter mammalian cell lines for the discovery of DDI2 inhibitors in multiple myeloma*. Cameron VanCleave, Brigham and Women's Hospital, Boston, MA United States.

A127: *Identification of therapeutic drug combinations targeting KRAS*. Masturah Mohd Abdul Rashid, KYAN Technologies Pte Ltd, Singapore, Singapore.

A128: *Analytical and clinical evaluation of a functional combinatorial precision medicine platform*. Masturah Mohd Abdul Rashid, KYAN Technologies Pte Ltd, Singapore, Singapore.

A129: *ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small-cell lung cancer*. Triparna Sen, Icahn School of Medicine at Mount Sinai, New York, NY United States.

A130: *Targeting mitogenic addiction as a therapeutic vulnerability in the neuroendocrine subtype of Small cell lung cancer*. Triparna Sen, Icahn School of Medicine at Mount Sinai, New York, NY United States.

A131: *Cumulative burden of fatty liver and kidney cancer in young-aged men: A national population-based study*. Hee Yeon Lee, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of.

A132: *Pathological Analysis of a Newly Established Immunocompetent Mice with Full Hpv16 Genome Integration*. Xue Li, UNC at Chapel Hill, Chapel Hill, NC United States.

A134: *Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors*. Brett Hall, Immuneering, San Diego, CA United States.

A135: *Are survival benefits of new drugs in combinations due to modest benefits in most patients or large benefits in few patients?* Haeun Hwangbo, The University of North Carolina at Chapel Hill, Chapel Hill, NC United States.

A136: *Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles*. Weijie Zhang, University of Minnesota, Minneapolis, MN United States.

A137: *Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers*. Genevive Hernandez, IGM Biosciences, Mountain View, CA United States.

A138: *Preclinical pharmacokinetic-pharmacodynamic modeling guides setting of the human starting dose of DS-1471a, a novel anti-CD147 antibody*. Miki Yokoyama, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

A139: *Preclinical characterization and prediction of human pharmacokinetics and efficacious dose for VIP236, a novel alpha V beta 3 binding small molecule-drug conjugate (SMDC)*. Melanie M. Frigault, Vincerx Pharma, Inc., Palo Alto, CA United States.

A140: *A physiologically based pharmacokinetic modeling approach for predicting the exposure of irinotecan and its active metabolite (SN-38) in cancer patients*. Kristina Zoran Denic, Mayo Clinic, Rochester, MN United States.

A141: *Preclinical pharmacokinetic (PK) and tumor growth inhibition (TGI) modeling for mANK-101, an anchored murine interleukin-12 (IL-12) complex for intratumoral administration for solid cancer*. David Hodson, Physiomics plc, Oxford, United Kingdom.

A142: *Fragment based discovery of inhibitors of the eIF4E:eIF4G interaction*. Caroline J. Richardson, Astex, Cambridge, United Kingdom.

A143: *Coupling fragment-based screening with targeted protein degradation and genetic rescue to identify and explore the function of a non-canonical pocket on eIF4E*. Paul A. Clarke, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, United Kingdom.

A144: *HM99462, a Novel potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inhibitor, MEK inhibitor, or EGFR mutant inhibitor*. Jaeyul Choi, Hanmi Pharm.Co.,Ltd., Hwaseong-si, Korea, Republic of.

A145: *CBFβ supports global protein translation in osteosarcoma and may provide a new therapeutic target*. Nicholas A. Oldberg, University of California, Davis, CA United States.

A146: *FPI-2068: A novel anti-EGFR/cMET, alpha-particle emitting, radioimmunoconjugate for cancer therapy*. John Forbes, Fusion Pharmaceuticals, Hamilton, ON Canada.

A147: *A HER2 targeted polylysine dendrimer nanoparticle radiotheranostic demonstrates excellent tumor accumulation, rapid clearance from circulation, and promising performance in PET-CT imaging*. Jeremy R.A. Paull, Starpharma Pty Ltd, Melbourne, Australia.

A148: *The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts*. Zhiyi Xue, Mayo Clinic, Rochester, MN United States.

A149: *Characterization of HER3 targeted radioligand therapy using molecular imaging*. Helen Kotanides, Actinium Pharmaceuticals, Inc., New York, NY United States.

A150: *Effects of radioimmunotherapy on human and canine osteosarcoma microenvironment*. Sabeena Giri, University of Saskatchewan, Saskatoon, SK Canada.

A151: *Establishing assays to investigate combinations of fractioned radiotherapy with DNA damage response agents in vitro and in vivo to enable investigation of radiosensitization and improved anti-tumour responses*. Graeme E. Walker, Sygnature Discovery, Macclesfield, United Kingdom.

A152: *The oncogene MYC as a driver of circadian clock disruption and dedifferentiation in the lung: Implications in early lung carcinogenesis*. Juliana Cazarin de Menezes, University of Rochester, Rochester, NY United States.

A153: *ALK proximitome reveal SLC3A2, part of the polyamine transporter, as a membrane interaction partner with growth promoting ability*. Bengt Hallberg, Inst. of Biomedicine, Gothenburg, Sweden.

A154: *PDLIM2 is required for regulating inflammation and cellular redox levels in mouse colorectal epithelial model*. Rosemary O'Connor, University College Cork, Cork, Ireland.

A155: *The TGF-β/BMP signaling cascades induce opposing fates in breast cancer and medulloblastoma through chromatin and cell cycle modulation*. Mohamad Moustafa Ali, Uppsala University, Uppsala, Sweden.

A158: *Rational Development of Synergistic Therapies Alongside BMI1 Inhibition for Group 3 Medulloblastoma*. David Bakhshinyan, McMaster University, Hamilton, ON Canada.

A159: *Mechanisms of uveal melanoma sensitivity to velcrin treatment and SLFN12-mediated cancer cell death*. Kristyna Kotynkova, Broad Institute of MIT and Harvard, Boston, MA United States.

A160: *The FGFR axis is a potential radiosensitization target*. Takahiro Oike, Gunma University, Maebashi, Japan.

A161: *A differentiation based therapeutic approach for KMT2A rearranged leukemia in infants and children*. Ritul Sharma, University of Calgary, Calgary, AB Canada.

A162: *A Comprehensive Platform for Unraveling the Molecular Mechanisms and Vulnerabilities of Colorectal Cancer: A Step Forward in Target Discovery*. Marcin Duleba, Ryvu Therapeutics, Krakow, Poland.

A163: *Exoribonuclease XRN1 is a Therapeutic Vulnerability in Tumors with Intrinsically Elevated Type I Interferon Signaling*. Maureen Lynes, Accent Therapeutics, Lexingtom, MA United States.

A164: *Activity of Dual BET and CDK9 Inhibition in Pancreatic Ductal Adenocarcinoma Informed from KinderMiner Prediction*. Austin Stram, University of Wisconsin - Madison, Madison, WI United States.

A165: *FGFR alterations in pediatric cancers: Opportunity for targeted therapy*. Ivan Li, Tufts University, Medford, MA United States.

A166: *CRISPR-Cas9 genome editing in iPSCs for functional genetic screening*. Paul Diehl, Cellecta, Inc., Mountain View, CA United States.

A167: *Cellular fitness of MYC-driven cancer cells to genetic and pharmacologic perturbations in normoxia, hypoxia and 3D culture*. Jun Yang, St Jude Children's Research Hospital, Memphis, TN United States.

A168: *T cell receptor-based bispecific molecules targeting KRAS neoantigen cancer driver mutations*. Andrew D. Whale, Immunocore Ltd, Oxford, United Kingdom.

A169: *Overcoming tumor-associated immune suppression and resistance to cancer immunotherapy using Hyal2-ADCC*. Sergei Kusmartsev, University of Florida, Gainesville, FL United States.

A170: *Discovery of Small Molecule Inhibitors of ADAR1*. Shane M. Buker, Accent Therapeutics, Lexington, MA United States.

A172: *TP-317, a first-in-class resolvin E1 small molecule, drives adjuvant efficacy in solid tumors by engaging innate and adaptive anti-tumor immunity in the tumor microenvironment (TME) and has neoadjuvant potential*. John F. Parkinson, Thetis Pharmaceuticals, Danbury, CT United States.

A173: *ASP2074, a novel tetraspanin 8 x CD3 bispecific antibody, demonstrates selectivity and antitumor activity in preclinical cancer models*. Masashi Shimazaki, Astellas Pharma Inc., Tsukuba, Japan.

A174: *Antitumor activity of lipid nanoparticle-delivered anti-miR-21*. Yongsheng Yang, The Whiteoak Group, Inc., Rockville, MD United States.

A175: *A Comparative Meta-Analysis of Survival Outcomes in Non-Small Cell Lung Cancer: Influence of Tumor Mutational Burden and KEAP1, KRAS, STK11 Mutations on the Efficacy of Immunotherapy Combined with Chemotherapy versus Chemotherapy Alone*. Muhammed Khaled Elfaituri, University of Tripoli, Tripoli, Libya.

A176: *Loss of SMAD4 unleashes mTOR and increases dependency on cap-dependent translation in esophageal tumorigenesis*. Nicholas J. Clemons, Peter MacCallum Cancer Centre, Melbourne, VIC Australia.

A177: *In vivo TuBa-seq Growth Profiling Identifies a Differential Role of the Tbx2 Subfamily in Oncogene-Negative Versus Kras-driven Lung Cancers*. Athar Khalil, Case Western Reserve University, Cleveland Heights, OH United States.

A178: *Therapeutic potential of a p14ARF minimal domain peptide in non-small cell lung cancer*. Anna L. Grobelny, Washington University, St. Louis, MO United States.